Stock FGEN FIBROGEN, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Press Releases FibroGen, Inc.

Equities

FGEN

US31572Q8087

Market Closed - Nasdaq
Other stock markets
 04:00:00 2024-05-09 pm EDT 		5-day change 1st Jan Change
1.22 USD +7.96% Intraday chart for FibroGen, Inc. +7.96% +37.65%
May. 07 Top Premarket Gainers MT
May. 06 Transcript : FibroGen, Inc., Q1 2024 Earnings Call, May 06, 2024

Press Releases

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Investor Spotlight: Companies Poised for Growth Amid Recent Developments: VTAK, ESPR, FGEN, GSUN, INBS
AQ
FibroGen : Corporate Presentation – May 2024
PU
FibroGen to Participate in Upcoming Investor Conferences
AQ
FibroGen: Q1 Earnings Snapshot
AQ
FibroGen Reports First Quarter 2024 Financial Results
AQ
FibroGen to Report First Quarter 2024 Financial Results
AQ
FibroGen Announces Clinical Data from Dose Escalation Phase 1b Study of FG-3246 (FOR46) in Combination with Enzalutamide in Patients with Metastatic Castration Resistant Prostate Cancer will be Presented at the 2024 American Society of Clinical Oncology Annual Meeting
AQ
FibroGen Announces Topline Results from Phase 1 Monotherapy Study of FG-3246 in Patients with Metastatic Castration-Resistant Prostate Cancer
AQ
FibroGen to Present at 23rd Annual Needham Virtual Healthcare Conference
AQ
FibroGen : Corporate Presentation – March 2024
PU
FibroGen Appoints Deyaa Adib, M.D. as Chief Medical Officer
AQ
FibroGen : Corporate Presentation – March 2024
PU
FibroGen: Q4 Earnings Snapshot
AQ
FibroGen Reports Fourth Quarter and Full Year 2023 Financial Results
AQ
FibroGen Regains All Rights to Roxadustat from AstraZeneca in the United States and Other AstraZeneca Territories, Except China and South Korea
AQ
FibroGen to Report Fourth Quarter and Full Year 2023 Financial Results
AQ
FibroGen To Host Part I of Virtual KOL Investor Event Series to Review Pamrevlumab Clinical Program in Pancreatic Cancer on February 13, 2024
AQ
FibroGen Announces Completion of the Pamrevlumab Arm in Precision Promise, Pancreatic Cancer Action Network’s Phase 2/3 Adaptive Platform Trial for Metastatic Pancreatic Cancer
AQ
FIBROGEN ALERT: Bragar Eagel & Squire, P.C. is Investigating FibroGen, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
BU
FibroGen Presents Data from Phase 3 MATTERHORN Trial of Roxadustat in Patients with Anemia of Lower Risk Transfusion-Dependent Myelodysplastic Syndromes at American Society of Hematology Annual Meeting
AQ
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. FGEN Stock
  4. News FibroGen, Inc.
  5. Press Releases
-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
SIGN UP NOW